Trending...
- Communities In Schools of Eastern Pennsylvania Honors United Way and Local Leaders
- New Research Spotlight, Expanding TUSC2 Science & Strategic Development Milestones Put Gene Therapy Innovation into Focus for Genprex (NAS DAQ: GNPX)
- Conservative Latinos for PA PAC Endorses Stacy Garrity for Governor: "Pennsylvania's Latino Families Need a Leader Who Delivers"
PHILADELPHIA--(BUSINESS WIRE)--Audacy announced a multiplatform partnership with mental health innovator Genomind. This breakthrough partnership taps into Audacy's influencers and Genomind's personalized genetic insights to bring mental health conversations into the mainstream.
As part of the partnership, Audacy will leverage the deep local connection of 15 stations across eight markets – Baltimore, Dallas, Houston, Los Angeles, New York, Philadelphia, San Diego and Washington D.C. – to promote Genomind's new Mental Health Map™, the first and only consumer DNA test to offer a concise, easy-to-navigate blueprint of your genetic profile and its influence on stress and anxiety, mood, focus and memory, habits and substance use, sleep, social behavior, and eating behavior.
Audacy and Genomind align in shared commitment to end the stigma surrounding mental health. Audacy's trusted voices and influencers will serve as ambassadors for the campaign – sharing their first hand experiences, using the Mental Health Map to learn more about their genetic makeup and predispositions toward mental health and wellness traits. Audacy is also among the first to provide Genomind as an employee benefit to help drive more engagement and action in mental health and wellness.
"Mental health awareness is a major area of focus for us and a crucial pillar of our companywide social impact platform, and we're excited to further activate our commitment through this partnership with Genomind," said Sarah Harris, Vice President, Social Impact, Audacy. "We recognize our significant influence and welcome the opportunity to use our voice, coupled with Genomind's mental health expertise, innovations and technology, to help improve and save lives and continue our shared mission of ending the stigma of talking about mental health."
More on The PennZone
"Genomind works to help all of us understand our personal mental health wiring and give people new insights and tools to manage and promote personalized mental health and wellness," said Kip Olmstead, President, Genomind. "Our partnership with Audacy scales our work allowing us to bring new mental health solutions to millions of Americans who may be suffering in silence or unsure of how to get started. Audacy's leadership in mental health is impressive and we are thrilled to find such a progressive and purpose-driven partner."
Genomind will also serve as the sponsor for Audacy's "I'm Listening Daily Capsules," 60-second daily public service announcements as part of the company's yearlong "I'm Listening" mental health initiative. Genomind will also serve as the presenting sponsor of Audacy's annual "I'm Listening" broadast, a live national program that brings together artists, athletes and medical specialists every September to remind listeners it's okay to not be okay, raise awareness and end the stigma of talking about mental health.
Audacy is committed to supporting the health and success of the communities that are the heart of its business. "I'm Listening" is a part of Audacy Serves, the Company's social impact platform that raises awareness of social issues and brings communities together for good. Audacy unites with its listeners and brands to support sound communities through several pillars of impact: mental health and anti-bullying, veterans and service members, children's health, the environment, civic education, and diversity, equity and inclusion.
More on The PennZone
About Audacy
Audacy, Inc. (NYSE: AUD) is a scaled, multi-platform audio content and entertainment company with the country's best radio broadcasting group, a leader in virtually every segment of audio, and America's #1 creator of original, premium audio. Audacy engages over 170 million consumers each month, bringing people together around the news, sports, podcasts and music that matter to them. Learn more at www.audacyinc.com, Facebook (Audacy Corp) and Twitter (@AudacyCorp).
About Genomind
Genomind is a leading precision mental health company singularly focused on filling the innovation gap in mental health care through novel, genetics-based tools. Supported by a world-class genetics lab, a unique heritage of clinical mental health expertise, clinical collaboration and consultation, state-of-the-art digital tools and telemental health enabling services, Genomind is empowering a new standard of care. Its flagship product, Genomind® Professional PGx Express™, is the most comprehensive pharmacogenetic testing service helping medical professionals personalize patients' mental health treatment. The Company also recently launched GenMed✓ Pro™ – Genomind's Smarter Precision Gene-Drug Interaction Software. This advanced medication management software was designed to help health professionals make safer prescribing decisions with speed and precision. In 2020 the company introduced the Genomind Mental Health Map™ – a breakthrough direct-to-consumer test that enables a new and better understanding of the biological basis of mental wellness, coupled with personalized actionable guidance to help people improve health and wellness. Learn more at https://www.genomind.com/.
As part of the partnership, Audacy will leverage the deep local connection of 15 stations across eight markets – Baltimore, Dallas, Houston, Los Angeles, New York, Philadelphia, San Diego and Washington D.C. – to promote Genomind's new Mental Health Map™, the first and only consumer DNA test to offer a concise, easy-to-navigate blueprint of your genetic profile and its influence on stress and anxiety, mood, focus and memory, habits and substance use, sleep, social behavior, and eating behavior.
Audacy and Genomind align in shared commitment to end the stigma surrounding mental health. Audacy's trusted voices and influencers will serve as ambassadors for the campaign – sharing their first hand experiences, using the Mental Health Map to learn more about their genetic makeup and predispositions toward mental health and wellness traits. Audacy is also among the first to provide Genomind as an employee benefit to help drive more engagement and action in mental health and wellness.
"Mental health awareness is a major area of focus for us and a crucial pillar of our companywide social impact platform, and we're excited to further activate our commitment through this partnership with Genomind," said Sarah Harris, Vice President, Social Impact, Audacy. "We recognize our significant influence and welcome the opportunity to use our voice, coupled with Genomind's mental health expertise, innovations and technology, to help improve and save lives and continue our shared mission of ending the stigma of talking about mental health."
More on The PennZone
- IEI Rugged IP66 Panel PC Brings Real-Time Visibility to Heavy-Duty Mining Fleets
- FDA Approval; Major Milestone for Preservative-Free Ketamine Ahead of FDA Goal Date for Treatment of Suicidal Depression by NRx Pharmaceuticals, Inc
- Building a Technology Powerhouse-From AI Drones and Global Acquisitions to Defense, Enterprise Software and the Future of Autonomous Operations $ZENA
- Shelter Structures America backs MATRA Second Life Project to turn retired tent vinyl into homes for displaced families
- P-Wave Press Announces Becoming Dad: Reflections for New Fathers by L. A. Davenport
"Genomind works to help all of us understand our personal mental health wiring and give people new insights and tools to manage and promote personalized mental health and wellness," said Kip Olmstead, President, Genomind. "Our partnership with Audacy scales our work allowing us to bring new mental health solutions to millions of Americans who may be suffering in silence or unsure of how to get started. Audacy's leadership in mental health is impressive and we are thrilled to find such a progressive and purpose-driven partner."
Genomind will also serve as the sponsor for Audacy's "I'm Listening Daily Capsules," 60-second daily public service announcements as part of the company's yearlong "I'm Listening" mental health initiative. Genomind will also serve as the presenting sponsor of Audacy's annual "I'm Listening" broadast, a live national program that brings together artists, athletes and medical specialists every September to remind listeners it's okay to not be okay, raise awareness and end the stigma of talking about mental health.
Audacy is committed to supporting the health and success of the communities that are the heart of its business. "I'm Listening" is a part of Audacy Serves, the Company's social impact platform that raises awareness of social issues and brings communities together for good. Audacy unites with its listeners and brands to support sound communities through several pillars of impact: mental health and anti-bullying, veterans and service members, children's health, the environment, civic education, and diversity, equity and inclusion.
More on The PennZone
- Logicraft Launches FuelDeck™, AI That Turns Aviation Fuel Tickets Into One Traceable Ledger
- Inaugural OC Tech Week Draws 3,000 From 12 Countries, Sends Finalist to $1M Startup World Cup
- Award-Winning American Hotelier Opens Art-Filled Luxury Cottage in Norfolk, England
- K2 Global / Ozi Amanat Named Among Top 100 AI Venture Capitalists in 2026
- Dr. Latorial Faison Appointed Poet Laureate of Virginia
About Audacy
Audacy, Inc. (NYSE: AUD) is a scaled, multi-platform audio content and entertainment company with the country's best radio broadcasting group, a leader in virtually every segment of audio, and America's #1 creator of original, premium audio. Audacy engages over 170 million consumers each month, bringing people together around the news, sports, podcasts and music that matter to them. Learn more at www.audacyinc.com, Facebook (Audacy Corp) and Twitter (@AudacyCorp).
About Genomind
Genomind is a leading precision mental health company singularly focused on filling the innovation gap in mental health care through novel, genetics-based tools. Supported by a world-class genetics lab, a unique heritage of clinical mental health expertise, clinical collaboration and consultation, state-of-the-art digital tools and telemental health enabling services, Genomind is empowering a new standard of care. Its flagship product, Genomind® Professional PGx Express™, is the most comprehensive pharmacogenetic testing service helping medical professionals personalize patients' mental health treatment. The Company also recently launched GenMed✓ Pro™ – Genomind's Smarter Precision Gene-Drug Interaction Software. This advanced medication management software was designed to help health professionals make safer prescribing decisions with speed and precision. In 2020 the company introduced the Genomind Mental Health Map™ – a breakthrough direct-to-consumer test that enables a new and better understanding of the biological basis of mental wellness, coupled with personalized actionable guidance to help people improve health and wellness. Learn more at https://www.genomind.com/.
0 Comments
Latest on The PennZone
- The Robert Travers Team of Long & Foster Marks 300+ Homes Sold, Expands Seller Representation
- CLINIMED Becomes First Liposuction Cannula Maker to Offer 3D and AR Models of Its Cannula Range
- RAS AP Consulting Advances 1099 Education and Readiness Initiative Through IFOL Training and Finance Technology Showcase
- Heritage at Manalapan Announces New 3.875% First-Year Mortgage Rate Buydown (7.11 APR)
- Conservative Latinos for PA PAC Endorses Stacy Garrity for Governor: "Pennsylvania's Latino Families Need a Leader Who Delivers"
- AthleteMerch.com Surpasses 100,000 Custom Items Delivered to Fans Nationwide
- MoMojo Records Signs Gary Nicholson
- Steve Weclew is Appointed by STS Capital Partners as Managing Director
- Communities In Schools of Eastern Pennsylvania Honors United Way and Local Leaders
- New Finnish Affiliate Site Ilmaiskierrokset.com Puts Wager-Free Spins in the Spotlight
- Major FDA Victory; Preservative-Free Ketamine Approved Ahead of November 10 Goal Date as Commercial Launch Opportunity Comes Into Focus for NRx Pharma
- Veterans Day Breakfast Celebration in Valley Forge to Honor America's Military Heroes
- Best Black Friday 2026 Deals on Lightweight Foldable Electric Wheelchairs – Save Up to 60%
- Immerse Yourself in the Historic Tochigi Autumn Festival, Celebrated Every Two Years Since 1874
- Resident Inspect Expands Virtual Property Inspections With AppFolio and Rentvine Integrations
- Unlocking the Next Phase of Growth with New AI Innovations; Targeting 2027 as Breakeven; Revenue Momentum Accelerates: ZenaTech (N A S D A Q: ZENA)
- Dr. Marilyn Pendelton Releases The Grief Reset to Address Grief Beyond Death
- AeroNet Deploys netElastic vBNG and CGNAT with Tarana Wireless to Deliver Scalable, Fiber-Class Broadband Across Puerto Rico
- New Atlas Maps the 38 States Behind Every Conversation
- Atlanta Company Launches Free, Ad-Free, Nonpartisan Voter Planning App for All 50 States Ahead of the Nov. 3 Election